共 28 条
[1]
[Anonymous], SKIN
[2]
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
[J].
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY,
2017, 76 (03)
:405-417
[3]
Coates LC, 2017, RMD OPEN, V3, DOI 10.1136/rmdopen-2017-000567